Crucell will receive an upfront payment of $1.5 million following the execution of the agreement and will be eligible for milestone payments of approximately $20 million. Further financial details of the agreement were not disclosed.
In September 2008, Crucell announced that it has signed an exclusive, commercial license agreement with North Carolina-based Talecris Biotherapeutics also for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6 cell line. For that deal Crucell received an upfront payment of $2.5 million and is eligible for milestone payments of approximately $30 million across multiple indications.